NCT03936933
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 50 Years (Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with confirmed signs or symptoms related to cerebral metastasis or radiographically-confirmed brain metastasis
https://ClinicalTrials.gov/show/NCT03936933